Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab.

Liu, Zhujun; Qin, Tingting; Yuan, Xiaohan; Yang, Jie; Shi, Wei; Zhang, Xiaoling; Jia, Yanan; Liu, Shaochuan; Wang, Jing; Li, Kai

Liu, Zhujun; Qin, Tingting; Yuan, Xiaohan; Yang, Jie; Shi, Wei; Zhang, Xiaoling; Jia, Yanan; Liu, Shaochuan; Wang, Jing; Li, Kai.

Affiliation

Liu Z; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Qin T; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Yuan X; Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Yang J; Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Shi W; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Zhang X; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
Jia Y; Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Liu S; Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Wang J; National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Li K; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.

Front Oncol ; 12: 875888, 2022.

Article de En | MEDLINE | ID: mdl-35664796

Mots clés

MMP2; N-cadherin; RGC32; TGFß; anlotinib; anlotinib abrogated bevacizumab resistance; bevacizumab; lung adenocarcinoma

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Front Oncol Année: 2022 Type de document: Article Pays d'affiliation: Chine Pays de publication: Suisse

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google